Doug Ingram, Sarepta CEO (Sarepta Therapeutics)
September 11, 2020 09:13 AM EDT
FDA+

Sarep­ta CEO Doug In­gram pins gene ther­a­py de­lay on Covid-bur­dened FDA, can't of­fer time­line for fix

Jason Mast

Editor

There are few dull days when it comes to Sarep­ta and the FDA.

The mus­cu­lar dy­s­tro­phy-fo­cused biotech, whose back-and-forth tra­vails with the agency have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times